

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

VEAS

Atty. Ref.: 1721-67

Serial No. cont of 09/913,525

Group: Unassigned

Filed: August 19, 2003

Examiner: Unassigned

For: IMMUNOGENIC COMPOSITIONS FOR USE AS
VACCINES

* * * * *

Assistant Commissioner for Patents
Washington, DC 20231

August 19, 2003

Sir:

INFORMATION DISCLOSURE STATEMENT

- ☒ 1. **PTO-1449 Pursuant to 37 CFR 1.97(b)**
[within 3 months of filing or prior to 1st Office Action on the merits]
N/C
- ☐ 2.(a) **Statement Pursuant to 37 CFR 1.97(c)**
[before Final Office Action or Allowance (requires Rule 97(e)
Statement or Rule 17(p) fee)]
N/C
- ☐ 2.(b) **Fee Payment Pursuant to 37 CFR 1.97(c)**
[before Final Office Action or Allowance (requires Rule 97(e)
Statement or Rule 17(p) fee)]
\$180.00
- ☐ 3. **Pursuant to 37 CFR 1.97(d)**
[after Final Office Action or Allowance (requires Rule 97(e)
Statement and Rule 17(p) fee), but before final fee payment]
\$180.00

The following are submitted in the above-identified application in compliance with
37 C.F.R. §§ 1.97 and 1.98:


- ☒ 4. A list of documents on Form PTO-1449, copies of each identified
document has been submitted and made of record in the parent
application Serial No. 09/913,525. Further copies of the cited

documents are not believed to be required however the office is requested to advise the undersigned if otherwise.

This paper is submitted in accordance with:

- ☒ 5. 37 CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action]
- ☐ 6. 37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier]; and
 - ☐ a) The required Statement made in item 8 below; or
 - ☐ b) The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 9 below.
- ☐ 7. 37 CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee payment]; and
 - ☐ a) The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith; and
 - ☐ b) The required Statement is stated in item 8 below.
- ☐ 8. Statement under 37 CFR 1.97(e)
 - ☐ a) The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or
 - ☐ b) No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.
- ☒ 9. Please charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of this document are enclosed.

Respectfully submitted,
NIXON & VANDERHYE P.C.

By: 

B. J. Sadoff
Reg. No. 36,663

1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

**INFORMATION DISCLOSURE
CITATION**

(Use several sheets if necessary)

ATTY. DOCKET NO.

1721-67

APPLICANT

VEAS

FILING DATE

Herewith

SERIAL NO.

cont of 09/913,525

GROUP

Unassigned

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
					YES	NO
WO97/26009	07/1997	WIPO				

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

	R. LACASSE ET AL.: "Fusion—competent vaccines: Broad neutralization of primary isolates of HIV." SCIENCE, vol. 283, no. 5400, 15 January 1999 (1999—01—15), pages 357—362, Washington, DC, Etats—Unis
	J. ROSSIO ET AL.: "Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins." JOURNAL OF VIROLOGY, vol. 72, no. 10, October 1998 (1998—10), pages 7992—8001, Baltimore, MD, Etats—Unis
	D. MONTEFIORI ET AL.: "Magic of the occult?" SCIENCE, vol. 283, no. 5400, 15 January 1999 (1999—01—15), pages 336—337, Washington, DC, Etats—Unis
	D. CHAN ET AL.: "HIV entry and its inhibition." CELL, vol. 93, no. 5, 29 May 1998 (1998—05—29), pages 681—684, Cambridge, MA, Etats—Unis
	K. SCHONNING ET AL.: "Frosne fusionskomplekser — en genvej til en HIV—vaccine? (Frozen fusion complexes — a shortcut to a HIV—vaccine?)" UGESKRIFT FOR LAEGER, vol. 161, no. 31, 2 August 1999 (1999—08—02), pages 4415—4416, Copenhagen, Danemark le titre
	Q. SATTENTAU ET AL.: "Antibody neutralization of HIV—1 and the potential for- vaccine design." IMMUNOLOGY LETTERS, vol. 66, no. 1—3, March 1999 (1999—03), pages 143—149, Amsterdam, Pays—Bas
*Examiner	Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)

